BibTex format
@article{Bengoetxea:2026:10.1111/jnc.70477,
author = {Bengoetxea, de Tena I and Sallie, FN and Rodriguez, Abiero A and Rizzi, B and Champarini, LG and Corti, E and Masella, G and Dunn, AL and Binder, LB and Wenzel, TJ and Robles, AI and Anversa, RG and Tremblay, C and Fokoua, AR and de, Lima RMS and D'脕vila, M and Truong, TTT and Pierce, JC and Rodrigues, RS and Dinamarca-Villarroel, L and Almeida, FB and Piironen, A-K and Aguiar, AFL and Jaramillo, AM and Santos, L and de, Lange A and Nutt, DJ and Lawrence, AJ},
doi = {10.1111/jnc.70477},
journal = {J Neurochem},
title = {Towards Mechanism-Informed Treatments for Mental Health.},
url = {http://dx.doi.org/10.1111/jnc.70477},
volume = {170},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Neuropsychiatric disorders represent a significant global health burden. Despite decades of research, current treatments typically provide only symptomatic relief, rather than addressing the underlying mechanisms of these conditions. Historically, research focused on the dopaminergic and serotonergic systems, which are deeply involved in the pathophysiology of many mental health disorders, including depression, schizophrenia, anxiety, autism spectrum disorder (ASD), and different substance use disorders, including alcohol use disorder (AUD). However, therapies targeting these systems have limitations, often only producing partial symptom relief plus compliance-limiting side effects. This highlights the need for improved treatments that may emerge from a broader understanding of the neurobiological bases of these conditions, especially neurochemical systems beyond dopamine and serotonin. Additional monoamines (e.g., histamine, acetylcholine, norepinephrine), neurolipid systems (e.g., endocannabinoids), and diverse signaling molecules such as neuropeptides, trace amines, and cytokines are increasingly recognized as key players in the dysfunction of neural circuits. In this review, which originated from the International Society for Neurochemistry (ISN)/Journal of Neurochemistry 5th Flagship School in October 2024 held in Naxos, Greece, we describe the importance of these neuromodulatory systems in the pathophysiology of select neuropsychiatric disorders, discuss their potential as targets for therapeutic intervention, exploring how they may offer more effective, mechanism-based treatments. We also highlight recent clinical trials, underscoring the progress in advancing towards clinical application, as well as sex-specific neurobiological differences, a historically overlooked, yet fundamental determinant of the pathophysiology of neuropsychiatric disorders. We propose that expanding our focus beyond traditional monoamines offers a promising avenue for the development
AU - Bengoetxea,de Tena I
AU - Sallie,FN
AU - Rodriguez,Abiero A
AU - Rizzi,B
AU - Champarini,LG
AU - Corti,E
AU - Masella,G
AU - Dunn,AL
AU - Binder,LB
AU - Wenzel,TJ
AU - Robles,AI
AU - Anversa,RG
AU - Tremblay,C
AU - Fokoua,AR
AU - de,Lima RMS
AU - D'脕vila,M
AU - Truong,TTT
AU - Pierce,JC
AU - Rodrigues,RS
AU - Dinamarca-Villarroel,L
AU - Almeida,FB
AU - Piironen,A-K
AU - Aguiar,AFL
AU - Jaramillo,AM
AU - Santos,L
AU - de,Lange A
AU - Nutt,DJ
AU - Lawrence,AJ
DO - 10.1111/jnc.70477
PY - 2026///
TI - Towards Mechanism-Informed Treatments for Mental Health.
T2 - J Neurochem
UR - http://dx.doi.org/10.1111/jnc.70477
UR - https://www.ncbi.nlm.nih.gov/pubmed/42152538
VL - 170
ER -
